# Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

> **NCT00065156** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 148 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00065156
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06-01
- **Primary completion:** 2008-08-01
- **Final completion:** 2008-08-01
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065156, "Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00065156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*